GLMD - Galmed Pharmaceuticals Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Galmed Pharmaceuticals Ltd.

16 Tiomkin Street
Tel Aviv 6578317
972 3 693 8448

Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Allen BaharaffCo-Founder, Pres, CEO & Chairman803.5kN/A1965
Mr. Doron CohenChief Financial Officer175.33kN/A1967
Mr. Guy NehemyaCOO & Data Protection Officer235.56kN/A1985
Mr. Yohai Stenzler CPAChief Accounting Officer239.48kN/A1983
Dr. Liat HayardenyChief Scientific Officer125.24kN/A1967
Ms. Yael HollanderVP of Legal Affairs & StrategyN/AN/A1983
Ms. Shani GanonHR Mang.N/AN/AN/A
Dr. Tali GorfineMedical ConsultantN/AN/A1970
Mr. Niv AlonHead of PMON/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.

Corporate Governance

Galmed Pharmaceuticals Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.